Innate Immune Cells in Melanoma: Implications for Immunotherapy
International Journal of Molecular Sciences · 05.08.2024 · 25 (15) · 8523
DOI: 10.3390/ijms25158523 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.08.2024. Verfasst von Marialuisa Trocchia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy. Hauptthemen laut MEDLINE: Melanoma, Immunity, Innate, Immunotherapy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Association for Cancer Research, CISILab Project (University of Naples Federico II).
Abstract (Originalsprache)
The innate immune system, composed of neutrophils, basophils, eosinophils, myeloid-derived suppressor cells (MDSCs), macrophages, dendritic cells (DCs), mast cells (MCs), and innate lymphoid cells (ILCs), is the first line of defense. Growing evidence demonstrates the crucial role of innate immunity in tumor initiation and progression. Several studies support the idea that innate immunity, through the release of pro- and/or anti-inflammatory cytokines and tumor growth factors, plays a significant role in the pathogenesis, progression, and prognosis of cutaneous malignant melanoma (MM). Cutaneous melanoma is the most common skin cancer, with an incidence that rapidly increased in recent decades. Melanoma is a highly immunogenic tumor, due to its high mutational burden. The metastatic form retains a high mortality. The advent of immunotherapy revolutionized the therapeutic approach to this tumor and significantly ameliorated the patients’ clinical outcome. In this review, we will recapitulate the multiple roles of innate immune cells in melanoma and the related implications for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medical Sciences (DiSMeT), University of Naples Federico II, 80138 Naples, Italy.
- Department of Internal Medicine and Clinical Immunology, University Hospital of Naples Federico II, 80138 Naples, Italy.
- Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80138 Naples, Italy.
- Melanoma, Cancer Immunotherapy, and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 80138 Naples, Italy.
ORCID-Profile: Leonardo Cristinziano, Anne Lise Ferrara, Francesco Palestra, Stefania Loffredo, Mariaelena Capone, Gabriele Madonna, Marilena Romanelli, Paolo Antonio Ascierto, Maria Rosaria Galdiero
Förderung
- Ministero della Salute
- Italian Association for Cancer Research
- CISILab Project (University of Naples Federico II)
- TIMING Project
- Campania Bioscience (Regione Campania)
Zitieren
APA
Trocchia, M., Ventrici, A., Modestino, L., Cristinziano, L., Ferrara, A. L., Palestra, F., Loffredo, S., Capone, M., Madonna, G., Romanelli, M., Ascierto, P. A., & Galdiero, M. R. (2024). Innate Immune Cells in Melanoma: Implications for Immunotherapy. International Journal of Molecular Sciences, 25(15), 8523. https://doi.org/10.3390/ijms25158523
Vancouver
Trocchia M, Ventrici A, Modestino L, Cristinziano L, Ferrara AL, Palestra F, et al. Innate Immune Cells in Melanoma: Implications for Immunotherapy. International Journal of Molecular Sciences. 2024;25(15):8523. doi:10.3390/ijms25158523
BibTeX
@article{Trocchia2024,
author = {Trocchia, Marialuisa and Ventrici, Annagioia and Modestino, Luca and Cristinziano, Leonardo and Ferrara, Anne Lise and Palestra, Francesco and Loffredo, Stefania and Capone, Mariaelena and Madonna, Gabriele and Romanelli, Marilena and Ascierto, Paolo Antonio and Galdiero, Maria Rosaria},
title = {Innate Immune Cells in Melanoma: Implications for Immunotherapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {15},
pages = {8523},
doi = {10.3390/ijms25158523}
}
EUVIMED